Perillyl alcohol for the treatment of temozolomide-resistant gliomas

Molecular Cancer Therapeutics

Volumn 11, Issue 11, 2012, Pages 2462-2472

  Cho, Hee Yeon ^a   Wang, Weijun ^a   Jhaveri, Niyati ^a   Torres, Shering ^a   Tseng, Joshua ^a   Leong, Michelle N ^a   Lee, David Jungpa ^a   Goldkorn, Amir ^b   Xu, Tong ^b   Petasis, Nicos A ^a   Louie, Stan G ^a   Schönthal, Axel H ^c   Hofman, Florence M ^a   Chen, Thomas C ^a,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NeOnc Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; CCAAT ENHANCER BINDING PROTEIN; GLUCOSE REGULATED PROTEIN 78; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PERILLYL ALCOHOL; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANIMALS; BRAIN NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM STRESS; GLIOMA; HUMANS; MICE; MONOTERPENES; NELFINAVIR; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PYRAZOLES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869227959     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0321     Document Type: Article

References (29)

1. Bailey HH, Attia S, Love RR, Fass T, Chappell R, Tutsch K, et al. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol 2008;62:149 -57.
2. Wiseman DA, Werner SR, Crowell PL. Cell cycle arrest by the isoprenoids perillyl alcohol, geraniol, and farnesol is mediated by p21 (Cip1) and p27(Kip1) in human pancreatic adenocarcinoma cells. J Pharmacol Exp Ther 2007;320:1163-70. (Pubitemid 46294051)
3. Yeruva L, Pierre KJ, Elegbede A, Wang RC, Carper SW. Perillyl alcohol and perillic acid induced cell cycle arrest and apoptosis in non small cell lung cancer cells. Cancer Lett 2007;257:216 - 26.
4. Chaudhary SC, Alam MS, Siddiqui MS, Athar M. Perillyl alcohol attenuates Ras-ERK signaling to inhibit murine skin inflammation and tumorigenesis. Chem Biol Interact 2009;179:145-53.
5. Da Fonseca CO, Masini M, Futuro D, Caetano R, Gattass CR, Quirico-Santos T. Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review. Surg Neurol 2006;66:611-5. (Pubitemid 44827176)
6. Da Fonseca CO, Silva JT, Lins IR, Simao M, Arnobio A, Futuro D, et al. Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol. Invest New Drugs 2009;27:557 - 64.
7. Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, Chow RH, et al. Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol Cancer Ther 2007;6:1262-75. (Pubitemid 46711989)
8. Jhaveri N, Cho H, Torres S, Wang W, Schonthal AH, Petasis NA, et al. Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Lett 2011;312:245-52.
9. Virrey JJ, Guan S, Li W, Schonthal AH, Chen TC, Hofman FM. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am J Pathol 2008;173:575-85.
10. Kanzawa T, Bedwell J, Kondo Y, Kondo S, Germano IM. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 2003;99:1047-52. (Pubitemid 44717401)
11. da Fonseca CO, Simao M, Lins IR, Caetano RO, Futuro D, Quirico-Santos T. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J Cancer Res Clin Oncol 2011;137:287-93.
12. Lebedeva IV, Su ZZ, Vozhilla N, Chatman L, Sarkar D, Dent P, et al. Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis. Mol Cancer Ther 2008;7:2042-50.
13. Reddy BS, Wang CX, Samaha H, Lubet R, Steele VE, Kelloff GJ, et al. Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res 1997;57:420-5. (Pubitemid 27081658)
14. Stark MJ, Burke YD, McKinzie JH, Ayoubi AS, Crowell PL. Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Cancer Lett 1995;96:15- 21.
15. Yuri T, Danbara N, Tsujita-Kyutoku M, Kiyozuka Y, Senzaki H, Shikata N, et al. Perillyl alcohol inhibits human breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 2004;84:251-60. (Pubitemid 38445375)
16. Virrey JJ, Liu Z, Cho HY, Kardosh A, Golden EB, Louie SG, et al. Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature. Mol Cancer Ther 2010;9:631-41.
17. Kardosh A, Golden EB, Pyrko P, Uddin J, Hofman FM, Chen TC, et al. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res 2008;68:843-51. (Pubitemid 351206762)
18. Pyrko P, Kardosh A, Wang W, Xiong W, Schonthal AH, Chen TC. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 2007;67:10920-8. (Pubitemid 350145921)
19. Weller M. Temozolomide and MGMT forever? Neuro-oncology 2010;12:219-20.
20. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26:4189-99.
21. Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 2007;67:9809-16. (Pubitemid 47621228)
22. Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett 2007;581:3641-51. (Pubitemid 47082516)
23. Virrey JJ, Dong D, Stiles C, Patterson JB, Pen L, Ni M, et al. Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells. Mol Cancer Res 2008;6:1268-75.
24. da Fonseca CO, Linden R, Futuro D, Gattass CR, Quirico-Santos T. Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol. Arch Immunol Ther Exp (Warsz) 2008;56:267- 76.
25. Beaupre DM, Cepero E, Obeng EA, Boise LH, Lichtenheld MG. R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Ther 2004;3:179-86. (Pubitemid 39193692)
26. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003;21:1624-36. (Pubitemid 46594118)
27. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
28. Talegaonkar S. MPR. Intranasal delivery: an approach to bypass the blood brain barrier. Ind J Pharmacol 2004;36:7.
29. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH II, et al. New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 2008;10:112-20.